|Videos|December 21, 2020

How SARS-CoV-2 Is Presenting in Infants

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

A new cases series report published in JAMA Network Open provided a look into what Canadian investigators believe is the first series of SARS-CoV-2 infected infants in their country.

The findings from the University of Sainte-Justine Center Hospital in Montreal describe infant patients presenting with mainly fever, mild disease, and no need for mechanical ventilation or intensive care treatment.

These results suggest that no additional SARS-CoV-2–related investigations may be necessary for the majority of infants.

This new data also show that signs and disease severity among observed infants differ from those reported in children and older adults. Infant patients had a predominance of gastrointestinal tract symptoms, even in the absence of fever, and mild disease overall.

In an interview with Contagion, study author Fatima Kakkar, MD, MPH, discussed the current understanding of SARS-CoV-2 infection in infants, as well as the limited rate of available data on such a patient group up until their research.

“When we first started, we came in with the premise that babies are going to be very sick,” Kakkar said. “We set up our COVID-19 wards that way. While we did have babies admitted, and we did see babies in our clinic with COVID, it was remarkable because they did very well.”


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Measles Update: October 9, 2026
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.